A Study to Investigate the Appearance and Disappearance of ASP3652 in Blood and Spinal Fluid in Healthy Male Subjects
A Phase I, Open-label Study to Investigate the Safety, Tolerability and Plasma and Cerebrospinal Fluid Pharmacokinetics and Pharmacodynamics of Multiple Doses of ASP3652 in Healthy Young Caucasian Male Subjects
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Screening takes place between Day -22 to Day -2. Subjects are admitted to the clinical on Day -1 and remain until Day 12.
On Days 5 to 9, subjects receive twice-daily doses of ASP3652, and a single dose on the morning of Day 10. Subjects fast for 10h before the morning dose on Days 5 to 9 and they are served the first standard meal 1h after the morning dose.
A spinal tap is used to collect cerebrospinal fluid (CSF) on Day 1 and Day 10. A plasma sample for PK sample is obtained before first dosing on Day 5. To confirm steady-state concentrations of ASP3652 in plasma, blood samples are obtained before the morning dose on Days 7, 9 and 10, and before the evening dose on Days 5, 7 and 9. On Day 10, a PK profile of ASP3652 in plasma is obtained for up to 48h after the morning dose and for up to 24h in CSF.
Profiles of several enzyme substrates in plasma and seminal fluid (exploratory) are obtained on Day 1 and Day 10 up to 24h in CSF and up to 48h in plasma, before the morning and evening dose on Days 5, 7 and 9 in plasma.
Vital signs, 12-lead electrocardiograms (ECGs), safety laboratory assessments, adverse events (AEs) and concomitant medication are monitored throughout the investigational period until the ESV.
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Harrow, Storbritannia, HA1 3UJ
- PAREXEL Early Phase Clinical Unit
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Subject is white and of Caucasian origin.
- Body Mass Index more than or equal to 18.5 and less than 30.0 kg/m2.
- Male subject must agree to practice an adequate contraceptive method with female sexual partners to prevent pregnancy.
Exclusion Criteria:
- Known or suspected hypersensitivity to ASP3652 or any components of the formulation used.
- History of excessive bleeding or bruising.
- Abnormalities of coagulation screen including platelet count, prothrombin time (PT) and activated partial thromboplastin time (aPTT).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: 1: ASP3652
Multiple doses of ASP3652
|
muntlig
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Pharmacokinetics (PK) of ASP3652 in plasma measured by area under the plasma concentration-time curve in the dosing interval (AUCtau)
Tidsramme: Days 5, 7 and 9, and Days 10 - 12
|
Days 5, 7 and 9, and Days 10 - 12
|
|
PK of ASP3652 in plasma measured by maximum observed plasma concentration (Cmax)
Tidsramme: Days 5, 7 and 9, and Days 10 - 12
|
Days 5, 7 and 9, and Days 10 - 12
|
|
PK parameter of ASP3652 in cerebrospinal fluid (CSF) measured by area under the plasma concentration-time curve in the dosing interval (AUCtau)
Tidsramme: Days 10 -11
|
Days 10 -11
|
|
PK parameter of ASP3652 in cerebrospinal fluid (CSF) measured by maximum observed plasma concentration (Cmax)
Tidsramme: Days 10 -11
|
Days 10 -11
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Additional PK of multiple doses of ASP3652 in plasma and cerebrospinal fluid (CSF)
Tidsramme: Plasma: Days 5, 7 and 9, and Days 10 - 12 / CSF: Days 10 -11
|
plasma concentration immediately before the next dose (Ctrough), time to attain Cmax (tmax), apparent terminal elimination half-life (t½), volume of terminal phase distribution at steady state (Vz/F), apparent clearance after oral administration at steady state (CL/F) and peak trough ratio (PTR)
|
Plasma: Days 5, 7 and 9, and Days 10 - 12 / CSF: Days 10 -11
|
|
Pharmacodynamics (PD) of multiple doses of ASP3652 in plasma and CSF
Tidsramme: Plasma: Days 1-3 and Days 5-12 / CSF: Days 1-2 and Days 10-11
|
response immediately prior to dosing (Rtrough), time of the maximum response (tmaxR), maximum response (Rmax), area under the response-time curve from 0 to 12h (AURC0-12h), percentage change in maximum response (Rmax%), percentage change in AURC from 0 to 12h (AUR0-12h%)
|
Plasma: Days 1-3 and Days 5-12 / CSF: Days 1-2 and Days 10-11
|
|
Safety and tolerability of multiple doses of ASP3652
Tidsramme: Screening (Day -22 to Day -2) to End-of-Study Visit (7 to 14 days after (early) discharge)
|
Screening (Day -22 to Day -2) to End-of-Study Visit (7 to 14 days after (early) discharge)
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- 3652-CL-0048
- 2011-004226-97 (EudraCT-nummer)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .